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Toxicogenomics:
Roadblocks and
New Directions
The toxicogenomics research community
may be “building a Tower of Babel” unless
it devises ways to communicate and share
data in a meaningful way among assorted
research groups and across research
platforms. Or so Bennett Van
Houten, acting science advisor for
the NIEHS Toxicogenomics Re-
search Consortium, told a newly
created National Research Council
(NRC) panel that convened 6
February 2003 to discuss focused
efforts to generate useful informa-
tion in toxicogenomics. 
Established at the behest of
NIEHS director Kenneth Olden
and deputy director Samuel
Wilson, the Committee on
Emerging Issues and Data on
Environmental Contaminants pro-
vides a public forum for communi-
cation among stakeholders about
new evidence and concerns not just
in toxicogenomics but also in envi-
ronmental toxicology, risk assess-
ment, exposure assessment, and
related fields.
Standardization of experiments,
vocabularies, and other activities
within and across DNA microarray
platforms is critical to toxicoge-
nomics, said consortium coordinator
Brenda Weis. “Currently, there are
no standard protocols for toxicoge-
nomics,” she said, adding that gene
annotation is one of the biggest
challenges facing the field. For
example, the pAC3 gene, a vector
commonly used to clone DNA
fragments, has been cited 59 differ-
ent ways in assorted research papers. [For
more on the topic of standardization, see
“Data Explosion: Bringing Order to Chaos
with Bioinformatics,” p. A340 this issue.]
Although researchers must be trained
in any new standards before they can be
implemented, the effort will be worth it:
such standards will ensure that results are
credible, that full data sets and annotations
are usable, that data from public reposito-
ries are accessible, and that data sets are
permanently available, said speaker Chris
Stoeckert, an associate professor of genetics
at the Penn Center for Bioinformatics at
the University of Pennsylvania. Projects
such as Minimum Information About a
Microarray Experiment, a workgroup of
the Microarray Gene Expression Data
Society (http://www.mged.org/), are
already working on standardization. 
Standardization poses many complex
challenges, however. For example, microar-
ray users must integrate such efforts with
existing ontology endeavors. Standardizing
protocols across a single platform even
within an individual company can be diffi-
cult when labs are scattered across the
country, said speaker Donna Mendrick,
vice president and scientific director for
toxicology at Gene Logic.
Ultimately, researchers may be
required to provide images along with
data to enhance quality control, Stoeckert
said, although the microarray community
is divided on this point, because the
images are valuable but expensive to store
and distribute. No decisions have yet
been made as to whether the NIEHS
consortium will reject data that don’t
meet whatever standards are eventually
enacted, Van Houten reported.
Other issues spring from standardization
problems. A federal liaison group organized
by the NIEHS has identified four poten-
tial roadblocks to the optimal use of toxi-
cogenomics, Wilson reported: premature
use of information without strong scien-
tific justification, communication of
flawed interpretations of data by
the scientific community, failure to
educate stakeholders (including
the public) on the new science,
and failure to fill information gaps.
“We need to ensure experiments
are in line with guidelines [being
developed by the toxicogenomics
community] for evolution of the
field,” Wilson said. He discussed
the need for a “roadmap” of the
field so that progress can be evalu-
ated against expected outcomes.
Risk assessment–oriented evalua-
tions of new chemicals and drugs
are also a priority.
Challenges exist for virtually all
conceivable applications of toxi-
cogenomics technologies, be they
industry efforts to build robust
predictive models for specific
agents across a single platform or
academic endeavors to collect
comprehensive amounts of data.
There are substantial concerns
about how toxicogenomics data
are going to be used and shared,
how proprietary databases will be
managed, and how potential priva-
cy issues will be handled.
To  address many of these
issues, the NRC committee is
evaluating three project proposals
generated by committee working
groups. These studies would
examine the potential impacts and
limitations of emerging technologies—
genomics, proteomics, toxicogenomics,
and bioinformatics—on risk assessment,
environmental decision making, toxicolo-
gy research, and public health, as well as
whether current knowledge bases and
tools fit the needs of scientific researchers
and public health policy makers and
workers. The standing committee itself
will not conduct these studies but will
recommend them for separate NRC
approval and funding. –Julie Wakefield
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Environews Forum
A complex system that works is invariably found to 
have evolved from a simple system that worked.
John Gall, Systemantics (1977)
The road ahead. Committees of scientists are working to chart a
course for the progress of toxicogenomics.Forum
Environmental Health Perspectives • VOLUME 111 | NUMBER 6 | May 2003 A 335
P
h
o
t
o
D
i
s
c
;
 
i
n
s
e
t
:
 
R
i
c
h
a
r
d
 
G
i
l
l
i
l
a
n
/
C
o
r
n
e
l
l
 
T
h
e
o
r
y
 
C
e
n
t
e
r
Rapamycin Throws
a Master Switch
Research on the potential anticancer drug
rapamycin has revealed a possible new
mechanism for suppressing large numbers
of genes simultaneously, rather than each
gene individually. Normally, genes are indi-
vidually activated or inactivated by proteins
targeted to the specific genes. But recent
research led by principal investigator X. F.
Steven Zheng, an assistant professor of
pathology at the School of Medicine of
Washington University in St. Louis,
Missouri, shows that a protein named “tar-
get of rapamycin,” or TOR, acts on many
different genes simultaneously, producing a
stress response that can stop cancer cells
from reproducing. The study is published in
the December 2002
issue of Molecular Cell. 
Zheng and col-
leagues studied the
molecular action of
rapamycin, which cur-
rently is used to suppress
the immune system
after kidney transplant.
The drug is derived
from the soil bacterium
Streptomyces hygroscopi-
cus, native to the island
of Rapa Nui (Easter
Island). Rapamycin reg-
ulates a myriad of
diverse cellular func-
tions at the level of tran-
scription and translation
by  inhibiting TOR.
Clinical studies show that rapamycin also
appears to both inhibit the formation of
tumors and suppress tumor angiogenesis
(the development of the blood vessels a
tumor needs to obtain nutrients from its
host), thus taking double-barreled aim at
human cancers. These unique properties
have led physicians to test its use as an anti-
cancer drug. 
In  an approach known as “chemical
genomics,” Zheng and colleagues used
rapamycin to inactivate TOR in yeast in a
collection of mutant yeast strains, one for
each gene in the yeast genome and each lack-
ing one gene. This enabled them to measure
how TOR interacts with each yeast gene,
using rapamycin sensitivity (how much
growth is inhibited by the drug) as a gauge. 
Zheng and his team found about 300
yeast genes to be associated with TOR-
related activities. The product of one such
gene is a protein known as silent informa-
tion regulator 3, or Sir3, which clings to
the genes responsible for stress proteins,
thereby inactivating them and keeping
them silent. Sir3 appears to be the key to
TOR’s multigene activity: When rapa-
mycin inactivated TOR, Sir3 molecules
began detaching themselves from the
chromatin regions carrying stress protein
genes. This triggered a stress response;
cells started producing stress proteins,
their walls thickened, and they stopped
proliferating. This is likely one of several
mechanisms that contribute to shutting
down cancerous  cells. Michael McDaniel,
a professor of pathology and immunology
at the Washington University in St. Louis
School of Medicine, calls it “a novel tran-
scriptional mechanism that may further
enhance the use of
rapamycin as an anti-
cancer agent.”
Moreover, the re-
searchers found that
when rapamycin sup-
pressed TOR, it also
interrupted nutrient
processing pathways,
thereby preventing
yeast cells from using glucose to produce
energy and amino acids to make new pro-
teins. Zheng and his team suggest that
when rapamycin inhibits TOR, it works by
eliciting a number of responses such as
those of stress and starvation. Such
responses are believed to cause cells to stop
proliferating.
McDaniel notes that a key feature of
rapamycin’s overall mechanism of action—
its ability to block cellular growth and pro-
liferation—extends to normal, healthy cells
as well as cancerous ones. He suggests that
these potential adverse effects of rapamycin
may be minimized by short-term use and
the optimization of drug doses. He adds
that Zheng’s genomic study in yeast should
provide a detailed map of the pathways by
which the drug works, which will help in
devising better therapeutic interventions
for relevant human diseases. 
The knowledge developed from the
study of rapamycin’s action needs to be
verified in human cells, particularly
tumor cells. If these results are borne out
and the side effects are not intolerable,
the result may be a new approach to
causing malignant tumors to go into
remission. If certain types of cancer are
not  fully cured, they might at least be
upgraded from fatal diseases to manage-
able chronic diseases. –Julian Josephson
CANCER
Origin of hope? New research shows that the immunosuppressant drug rapamycin, isolated from a
bacterium native to Rapa Nui (Easter Island), acts as a link to bring together two immune system pro-
teins. This association halts cell division, which may make the drug useful in the treatment of cancer.A 336 VOLUME 111 | NUMBER 6 | May 2003 • Environmental Health Perspectives
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Since the first seminal paper on genomics
appeared in the 20 October 1995 issue of
Science, coverage has grown rapidly to some
3,000–4,000 reports yearly, many on
gene–environment interactions, according
to NIEHS deputy director Samuel Wilson.
The influx of new data is revealing many
surprises, many described at the 42nd
annual meeting of the Society of
Toxicology, held 9–13 March 2003 in Salt
Lake City, Utah.
Just 15 years ago, researchers could
study how toxicants alter only individual
genes, and they spent years dissecting
single genes. This approach was grossly
inadequate, because “genes do not act in
isolation, but by talking to other genes,”
says Kenneth Ramos, chairman of the
Department of Biochemistry and Mol-
ecular Biology at Kentucky’s University of
Louisville School of Medicine and toxi-
cogenomics editor of EHP. Today, DNA
microarrays capture the expression of
thousands of genes in response to environ-
mental stressors.
Ramos and colleagues study molecular
and genetic impacts of environmental con-
taminants—including the polycyclic
hydrocarbon benzo[a]pyrene (BaP)—on
heart disease and cancer. In a study of
mouse vascular cells exposed to BaP, 1,383
of 9,000 genes were altered. Many affected
genes regulate cell growth and differentia-
tion; the big surprise, says Ramos, was that
BaP also affects genes involved in immune
modulation, such as those of the class I his-
tocompatibility complex. “Our findings
link immune cell activation as a key molec-
ular event in the BaP-induced atherogenic
response,” he says. This fits well with in
vivo observations that immune cells infil-
trate the arterial wall in the early stages of
atherosclerosis. 
Leona Samson, a professor of toxicology
at the Massachusetts Institute of Tech-
nology in Cambridge, described her work
with Saccharomyces cerevisiae. She used S.
cerevisiae mutants, each missing one gene,
to identify genes that help cells recover
from damage by the alkylating agent
methylmethane sulfonate (MMS). Of the
6,000 yeast genes, about 400 are sensitive
to MMS, including genes related to cell
death and DNA repair. But most of the
recovery genes Samson identified are
involved with functions such as cytoskele-
ton remodeling, protein degradation, RNA
synthesis, and lipid metabolism. The new
data suggest that to recover from DNA
damage and avoid cell death, “cells have a
lot of other things to repair,” says Samson.
She and her colleagues are examining
recovery pathways for other alkylating
agents and ultraviolet light, and each shows
a unique pattern. She says the goal is to
“predict whether a cell, organism, or even
person will recover from damage.” 
Yet another surprise came from
research at the NIEHS National Center
for Toxicogenomics (NCT), where the
gene  Dss1—previously associated only
with a developmental abnormality of the
hands and feet—was found to play a role
in skin cancer. In mouse skin cells treated
with phorbol ester tumor promoters, Dss1
was expressed during early stages of tumor
formation. “There is no previously recog-
nized basis for predicting a role of Dss1 in
skin tumorigenesis,” says NCT director
Raymond Tennant. 
Scientists are uncovering many new
genes and pathways never before imagined
to be associated with gene–environment
responses. A key next step is “phenotypic
anchoring,” connecting specific gene
changes to markers of toxicity [see NCT
Update, p. A338 this issue]. In a proof-of-
concept experiment on phenotypic anchor-
ing, researchers in Richard Paules’s NCT lab
monitored liver toxicity in rats induced by
the drug methapyrilene. They verified that
the expression of a group of genes corre-
sponds to histological changes such as liver
necrosis and periportal inflammation.
In addition to the data presented at the
annual meeting, another source of informa-
tion was unveiled—EHP’s  new Toxico-
genomics Section. This section will appear
quarterly and will present news, research,
and perspectives in toxicogenomics and
related disciplines. –Carol Potera
Putting Proteins
in One Place
The growing wealth of information about
the human proteome—the hundreds of
thousands of proteins at work in the human
body—is useful only if scientists can get
their hands on it. To give researchers faster
worldwide access to high-quality protein
data, the National Human Genome
Research Institute (NHGRI) and five other
institutes and centers of the NIH have
awarded $15 million to create a compre-
hensive, public data bank of protein
sequences. 
The United Protein Database, or
UniProt, will combine three existing data-
bases—Swiss-Prot, TrEMBL, and the
Protein Information Resource (PIR). By
the end of the three-year grant, UniProt
should contain annotated entries on more
than 2 million proteins, including infor-
mation on protein sequences, functions,
modifications, and other characteristics.
UniProt brings together scientists and
resources that complement one another,
says Peter Good, program director for
genome informatics and computational
biology at the NHGRI. The database will
combine 830,000 entries from TrEMBL,
123,000 entries from Swiss-Prot, and
283,000 entries from PIR. 
TrEMBL contains more entries
because it is a computational database—
computer programs use the protein
sequences to make predictions of protein
function. Swiss-Prot uses the more time-
consuming hand-annotation method,
which means that a scientist reads articles
that mention a particular protein, extracts
the relevant information, then adds it to
the database. PIR, operated by George-
town University Medical Center and the
National Biomedical Research Foundation
in Washington, D.C., contains both com-
puter-annotated and hand-annotated
entries. The PIR will cease to be updated,
and its staff will assist with hand-annotating
the TrEMBL records.
PIR will also contribute its “protein
family” method of classification, which
groups proteins by function based on
sequence similarity. If two proteins fall into
the same family, scientists can infer that the
proteins may have similar functions. This
method—created by one of the pioneers of
protein sequence databases, Margaret
Dayhoff—has been developed further by
Cathy Wu, director of bioinformatics for
PIR and one of the principal investigators
of UniProt. 
MEETING REPORT BIOINFORMATICS
The latest. New findings and a new EHP sec-
tion on toxicogenomics were unveiled at SOT.Other UniProt principal investigators are
Rolf Apweiler, who is head of the Sequence
Database Group at the European Bio-
informatics Institute, and Amos Bairoch, who is
group leader of the Swiss-Prot Group at the
Swiss Institute of Bioinformatics. 
Any biomedical scientist interested in pro-
tein function will benefit from the new data-
base, Good says. Drug discovery in particular
involves pinpointing proteins that are altered in
diseased tissue, then exploring these proteins
further to determine if they will make good tar-
gets for new drugs. 
A typical proteomics experiment uses mass
spectrometry to identify proteins and parts of
their sequences. “The way to add meaning to
those sequences is to search databases, which
contain links to essentially all human knowledge
surrounding those protein targets,” says Tim
Haystead, an associate professor of pharmacolo-
gy and cancer biology at Duke University in
Durham, North Carolina, and founder of the
drug discovery company Serenex. Right now,
scientists have to search several different data-
bases to find all existing information on a
sequence. “A unified database will make it easi-
er for us,” Haystead says. 
William Pearson, a professor of biochem-
istry and molecular genetics at the University
of Virginia and a member of PIR’s oversight
and scientific advisory board, agrees that sci-
entists who work with protein sequence data
have been frustrated both by the need to
search multiple databases and by the some-
times contradictory information arising from
their provenance in different methods of
annotation. “When these [databases] all get
put together, they’re going to have much
more consistent ways of referencing data and
giving names to things,” he says. “It will be
much more efficient.” 
Funded in October 2002, UniProt is still a
work in progress. “Part of the challenge is getting
three groups that have different [organizational]
cultures to interact,” Good says. For continu-
ity, the three groups will maintain their current
search interfaces, each of which will eventually
access the entire UniProt database. UniProt
will also be accessible via a central website,
http://www.uniprot.org/. A basic version of
that site will be up this year, according to
Apweiler.
UniProt will be freely available to all, but
not until after the expiration of a license with
industry covering access to Swiss-Prot records
by  commercial users. The license for Swiss-
Prot records allowed the European Bio-
informatics Institute and the Swiss Institute of
Bioinformatics to continue developing Swiss-
Prot in the absence of government funding.
With support from the NIH, the entire
UniProt database will be available free of
charge for both academic and commercial
users by January 2005. –Angela Spivey
Forum
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Bioinformatics Organization txgnet
Bioinformatics—the rapidly evolving science of managing and ana-
lyzing biological data using advanced computing programs—is a
vital tool for evaluating the volumes of data generated by
genomics research. Bioinformatics Organization is a nonprofit inter-
national group with more than 5,500 members that is working to
promote the free and unrestricted exchange of bioinformatics
resources and data among all scientists, including those with little
funding or at small institutions, who may not be able to afford
access to cutting-edge resources through the usual channels. As
part of this mission, the group has established a forum for infor-
mation and data exchange at http://bioinformatics.org/.
The Bioinformatics FAQ page includes a brief discussion of how
the Human Genome Project has impacted bioinformatics and relat-
ed fields such as computational biol-
ogy and pharmacogenomics. The
page also provides overviews of the
technologies currently being used in
bioinformatics, lists of books, links
to university bioinformatics pro-
grams around the world, and por-
tals to web directories and tutorials.
This section also includes practical
advice for performing a number of common bioinformatics func-
tions and a glossary of commonly used terms.
Group members are currently involved in nearly 100 projects,
which are listed under the Hosted Projects header on the homepage.
Examples include ALiBio, a free online library of algorithms, and
BioQuery, which allows visitors to search multiple biomedical data-
bases simultaneously and automatically informs users when new
data matching a search query become available. Multi-Genome
Navigator, or MuGeN, is a software package that allows users to
explore multiple annotated genomes simultaneously. And GUI Blast
gives Windows users a graphical user interface for using Basic Local
Alignment Search Tool (BLAST) software.
The Research Laboratory section of the site contains databases
of, among other things, expressed sequence tag (EST) clusters.
Users of the EST database can clusterize publicly available EST
sequences and contigate them using a specific assembler known as
zEST. The site’s developers hope visitors will thus help build the
repository of EST clusters, which can be used in the discovery of
new genes, splice variants, and gene polymorphisms. Also available
in this section are databases of immigrant genes, leukemia genes,
and pancreatic cancer genes.
The main page lists current news items from sources including
journals, newspapers, government agencies, and software devel-
opers. Archived news items dating back to 2000 provide a look
back at the discipline’s progress. Registered users can post items of
interest to the rest of the bioinformatics community.
Since 2002, Bioinformatics Organization has awarded the
annual Benjamin Franklin Award to an individual its members feel
has “promoted freedom and openness in the field of bioinformat-
ics.” The 2003 award went to Jim Kent of the University of
California, Santa Cruz, who used his own GigAssembler program to
assemble the public fragments of the human genome before
Celera Genomics was able to assemble their private human
genome sequence. This helped keep these data in the public
domain. –Erin E. Dooley